Current status and potential of neutron capture therapy as a new treatment option for malignant soft tissue tumors
Neutron capture therapy(NCT), a type of radiation therapy for cancer, utilizes radiation emitted as a result of the reaction between neutron capture elements, such as boron(10B)and gadolinium(157Gd), located in the tumor and thermal neutrons irradiated from outside the body. In NCT with 10B(BNCT), t...
Gespeichert in:
Veröffentlicht in: | Drug Delivery System 2020/03/25, Vol.35(2), pp.137-145 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng ; jpn |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 145 |
---|---|
container_issue | 2 |
container_start_page | 137 |
container_title | Drug Delivery System |
container_volume | 35 |
creator | Andoh, Tooru Ichikawa, Hideki Fujimoto, Takuya Suzuki, Minoru |
description | Neutron capture therapy(NCT), a type of radiation therapy for cancer, utilizes radiation emitted as a result of the reaction between neutron capture elements, such as boron(10B)and gadolinium(157Gd), located in the tumor and thermal neutrons irradiated from outside the body. In NCT with 10B(BNCT), the homogeneous distribution of 10B in tumor tissues contributes to cancer treatment by selectively generating alpha rays in or near tumor cells, thereby destroying individual tumor cells in a brief irradiation session, without affecting surrounding normal tissues. With the success of a small-typed accelerator with NCT development and its setup in hospitals, NCT as a treatment for cancer will expand its potential and indications. In this report, an overview of current status of NCT in clinical studies is given. Then, our preclinical studies on the cellular uptake behavior and biodistribution of 10B and anti-tumor effects in treating soft tissue sarcoma by BNCT are described. In addition, the potential of a gadolinium formula as a new pharmaceutical agent with NCT is also discussed. |
doi_str_mv | 10.2745/dds.35.137 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2419470119</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2419470119</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2237-5caf359eb206a6b4d688f9da8313a2ac5cab9d94b7c15658574093345f32157f3</originalsourceid><addsrcrecordid>eNo9kE1Lw0AQhhdRsFYv_oIFb0LqfmST7MGDFL-g4EXPyyTZbVPSbJzdIP57t7T2NDDvM-_AQ8gtZwtR5uqhbcNCqgWX5RmZ8arimSilOCczprnMFGPFJbkKYctYnkI-I7icEO0QaYgQp0BhaOnoY9p00FPv6GCniH6gDYxxQkvjxiKMvxQSm8IfGtFC3O0r_Bi7RDqPdAd9tx5g3-tdpLELYUq3085juCYXDvpgb45zTr5enj-Xb9nq4_V9-bTKGiFkmakGnFTa1oIVUNR5W1SV0y1UkksQ0KS81q3O67LhqlCVKnOmpcyVk4Kr0sk5uTv0jui_Jxui2foJh_TSiJzrvGSc60TdH6gGfQhonRmx2wH-Gs7M3qlJTo1UJjlN8OMB3iZda3tCAWPX9PYfFUf-tG82gMYO8g8QFYHM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2419470119</pqid></control><display><type>article</type><title>Current status and potential of neutron capture therapy as a new treatment option for malignant soft tissue tumors</title><source>J-STAGE Free</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Andoh, Tooru ; Ichikawa, Hideki ; Fujimoto, Takuya ; Suzuki, Minoru</creator><creatorcontrib>Andoh, Tooru ; Ichikawa, Hideki ; Fujimoto, Takuya ; Suzuki, Minoru</creatorcontrib><description>Neutron capture therapy(NCT), a type of radiation therapy for cancer, utilizes radiation emitted as a result of the reaction between neutron capture elements, such as boron(10B)and gadolinium(157Gd), located in the tumor and thermal neutrons irradiated from outside the body. In NCT with 10B(BNCT), the homogeneous distribution of 10B in tumor tissues contributes to cancer treatment by selectively generating alpha rays in or near tumor cells, thereby destroying individual tumor cells in a brief irradiation session, without affecting surrounding normal tissues. With the success of a small-typed accelerator with NCT development and its setup in hospitals, NCT as a treatment for cancer will expand its potential and indications. In this report, an overview of current status of NCT in clinical studies is given. Then, our preclinical studies on the cellular uptake behavior and biodistribution of 10B and anti-tumor effects in treating soft tissue sarcoma by BNCT are described. In addition, the potential of a gadolinium formula as a new pharmaceutical agent with NCT is also discussed.</description><identifier>ISSN: 0913-5006</identifier><identifier>EISSN: 1881-2732</identifier><identifier>DOI: 10.2745/dds.35.137</identifier><language>eng ; jpn</language><publisher>Kawasaki: THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM</publisher><subject>Alpha rays ; Anticancer properties ; Boron ; Cancer ; Cancer therapies ; Gadolinium ; Gadolinium isotopes ; Health services ; Irradiation ; Neutrons ; Nuclear capture ; Phenylalanine ; Radiation ; Radiation therapy ; Reagents ; Sarcoma ; Soft tissue sarcoma ; Soft tissues ; Thermal neutrons ; Tissues ; Tumor cells ; Tumors</subject><ispartof>Drug Delivery System, 2020/03/25, Vol.35(2), pp.137-145</ispartof><rights>2020 The Japan Society of Drug Delivery System</rights><rights>Copyright Japan Science and Technology Agency 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2237-5caf359eb206a6b4d688f9da8313a2ac5cab9d94b7c15658574093345f32157f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids></links><search><creatorcontrib>Andoh, Tooru</creatorcontrib><creatorcontrib>Ichikawa, Hideki</creatorcontrib><creatorcontrib>Fujimoto, Takuya</creatorcontrib><creatorcontrib>Suzuki, Minoru</creatorcontrib><title>Current status and potential of neutron capture therapy as a new treatment option for malignant soft tissue tumors</title><title>Drug Delivery System</title><addtitle>DDS</addtitle><description>Neutron capture therapy(NCT), a type of radiation therapy for cancer, utilizes radiation emitted as a result of the reaction between neutron capture elements, such as boron(10B)and gadolinium(157Gd), located in the tumor and thermal neutrons irradiated from outside the body. In NCT with 10B(BNCT), the homogeneous distribution of 10B in tumor tissues contributes to cancer treatment by selectively generating alpha rays in or near tumor cells, thereby destroying individual tumor cells in a brief irradiation session, without affecting surrounding normal tissues. With the success of a small-typed accelerator with NCT development and its setup in hospitals, NCT as a treatment for cancer will expand its potential and indications. In this report, an overview of current status of NCT in clinical studies is given. Then, our preclinical studies on the cellular uptake behavior and biodistribution of 10B and anti-tumor effects in treating soft tissue sarcoma by BNCT are described. In addition, the potential of a gadolinium formula as a new pharmaceutical agent with NCT is also discussed.</description><subject>Alpha rays</subject><subject>Anticancer properties</subject><subject>Boron</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Gadolinium</subject><subject>Gadolinium isotopes</subject><subject>Health services</subject><subject>Irradiation</subject><subject>Neutrons</subject><subject>Nuclear capture</subject><subject>Phenylalanine</subject><subject>Radiation</subject><subject>Radiation therapy</subject><subject>Reagents</subject><subject>Sarcoma</subject><subject>Soft tissue sarcoma</subject><subject>Soft tissues</subject><subject>Thermal neutrons</subject><subject>Tissues</subject><subject>Tumor cells</subject><subject>Tumors</subject><issn>0913-5006</issn><issn>1881-2732</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo9kE1Lw0AQhhdRsFYv_oIFb0LqfmST7MGDFL-g4EXPyyTZbVPSbJzdIP57t7T2NDDvM-_AQ8gtZwtR5uqhbcNCqgWX5RmZ8arimSilOCczprnMFGPFJbkKYctYnkI-I7icEO0QaYgQp0BhaOnoY9p00FPv6GCniH6gDYxxQkvjxiKMvxQSm8IfGtFC3O0r_Bi7RDqPdAd9tx5g3-tdpLELYUq3085juCYXDvpgb45zTr5enj-Xb9nq4_V9-bTKGiFkmakGnFTa1oIVUNR5W1SV0y1UkksQ0KS81q3O67LhqlCVKnOmpcyVk4Kr0sk5uTv0jui_Jxui2foJh_TSiJzrvGSc60TdH6gGfQhonRmx2wH-Gs7M3qlJTo1UJjlN8OMB3iZda3tCAWPX9PYfFUf-tG82gMYO8g8QFYHM</recordid><startdate>20200325</startdate><enddate>20200325</enddate><creator>Andoh, Tooru</creator><creator>Ichikawa, Hideki</creator><creator>Fujimoto, Takuya</creator><creator>Suzuki, Minoru</creator><general>THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM</general><general>Japan Science and Technology Agency</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20200325</creationdate><title>Current status and potential of neutron capture therapy as a new treatment option for malignant soft tissue tumors</title><author>Andoh, Tooru ; Ichikawa, Hideki ; Fujimoto, Takuya ; Suzuki, Minoru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2237-5caf359eb206a6b4d688f9da8313a2ac5cab9d94b7c15658574093345f32157f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; jpn</language><creationdate>2020</creationdate><topic>Alpha rays</topic><topic>Anticancer properties</topic><topic>Boron</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Gadolinium</topic><topic>Gadolinium isotopes</topic><topic>Health services</topic><topic>Irradiation</topic><topic>Neutrons</topic><topic>Nuclear capture</topic><topic>Phenylalanine</topic><topic>Radiation</topic><topic>Radiation therapy</topic><topic>Reagents</topic><topic>Sarcoma</topic><topic>Soft tissue sarcoma</topic><topic>Soft tissues</topic><topic>Thermal neutrons</topic><topic>Tissues</topic><topic>Tumor cells</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Andoh, Tooru</creatorcontrib><creatorcontrib>Ichikawa, Hideki</creatorcontrib><creatorcontrib>Fujimoto, Takuya</creatorcontrib><creatorcontrib>Suzuki, Minoru</creatorcontrib><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Drug Delivery System</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Andoh, Tooru</au><au>Ichikawa, Hideki</au><au>Fujimoto, Takuya</au><au>Suzuki, Minoru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current status and potential of neutron capture therapy as a new treatment option for malignant soft tissue tumors</atitle><jtitle>Drug Delivery System</jtitle><addtitle>DDS</addtitle><date>2020-03-25</date><risdate>2020</risdate><volume>35</volume><issue>2</issue><spage>137</spage><epage>145</epage><pages>137-145</pages><issn>0913-5006</issn><eissn>1881-2732</eissn><abstract>Neutron capture therapy(NCT), a type of radiation therapy for cancer, utilizes radiation emitted as a result of the reaction between neutron capture elements, such as boron(10B)and gadolinium(157Gd), located in the tumor and thermal neutrons irradiated from outside the body. In NCT with 10B(BNCT), the homogeneous distribution of 10B in tumor tissues contributes to cancer treatment by selectively generating alpha rays in or near tumor cells, thereby destroying individual tumor cells in a brief irradiation session, without affecting surrounding normal tissues. With the success of a small-typed accelerator with NCT development and its setup in hospitals, NCT as a treatment for cancer will expand its potential and indications. In this report, an overview of current status of NCT in clinical studies is given. Then, our preclinical studies on the cellular uptake behavior and biodistribution of 10B and anti-tumor effects in treating soft tissue sarcoma by BNCT are described. In addition, the potential of a gadolinium formula as a new pharmaceutical agent with NCT is also discussed.</abstract><cop>Kawasaki</cop><pub>THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM</pub><doi>10.2745/dds.35.137</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0913-5006 |
ispartof | Drug Delivery System, 2020/03/25, Vol.35(2), pp.137-145 |
issn | 0913-5006 1881-2732 |
language | eng ; jpn |
recordid | cdi_proquest_journals_2419470119 |
source | J-STAGE Free; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Alpha rays Anticancer properties Boron Cancer Cancer therapies Gadolinium Gadolinium isotopes Health services Irradiation Neutrons Nuclear capture Phenylalanine Radiation Radiation therapy Reagents Sarcoma Soft tissue sarcoma Soft tissues Thermal neutrons Tissues Tumor cells Tumors |
title | Current status and potential of neutron capture therapy as a new treatment option for malignant soft tissue tumors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T11%3A11%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20status%20and%20potential%20of%20neutron%20capture%20therapy%20as%20a%20new%20treatment%20option%20for%20malignant%20soft%20tissue%20tumors&rft.jtitle=Drug%20Delivery%20System&rft.au=Andoh,%20Tooru&rft.date=2020-03-25&rft.volume=35&rft.issue=2&rft.spage=137&rft.epage=145&rft.pages=137-145&rft.issn=0913-5006&rft.eissn=1881-2732&rft_id=info:doi/10.2745/dds.35.137&rft_dat=%3Cproquest_cross%3E2419470119%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2419470119&rft_id=info:pmid/&rfr_iscdi=true |